Jesse I. Treu
Director/Board Member at Altea Therapeutics Corp.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Todd Brady | M | 52 |
Domain Associates LLC
 Domain Associates LLC Investment ManagersFinance Domain Associates LLC (Domain Associates) is a venture capital firm founded in 1985. The firm is headquartered in Princeton, New Jersey.
Helio Vision, Inc.
 Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | - |
| John Sheridan | M | 68 | 11 years | |
| Rebecca A. Stirn | F | 71 |
Aesthetic Sciences Corp.
 Aesthetic Sciences Corp. Pharmaceuticals: MajorHealth Technology Aesthetic Sciences Corp. provides aesthetic medicine and incontinence products. It develops dermal fillers based on polymer technologies for use in the aesthetic market. The company was founded by Edward Schmitt & Gary Petersmeyer in December 2004 and is headquartered in San Francisco, CA. | 20 years |
| Leigh Vosseller | F | 51 | 11 years | |
| Richard Douglas | M | 71 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 8 years |
| Shana Kelley | M | - |
Xagenic, Inc.
 Xagenic, Inc. Medical SpecialtiesHealth Technology Xagenic, Inc. develops the first lab-free molecular diagnostic platform. Its automated diagnostic platform will enable widespread decentralized testing to be performed outside of clinical laboratories. The firm's amplified redox assay detection technology utilizes electrochemical detection methods and does not rely on optical detection components or enzymatic amplification; crude samples can be analyzed with minimal sample processing. The company was founded by Shana O. Kelley and Edward Hartley Sargent in 2010 and is headquartered in Toronto, Canada. | 14 years |
| Kim Kamdar | M | 56 |
One Palmer Square Associates VIII LLC
Domain Associates LLC
Domain Associates LLC Investment ManagersFinance Domain Associates LLC (Domain Associates) is a venture capital firm founded in 1985. The firm is headquartered in Princeton, New Jersey. | 19 years |
| Martin Joyce | M | 70 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 11 years |
| Nancy Miller-Rich | F | 65 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 4 years |
| Eckard Weber | M | 73 |
Domain Associates LLC
Domain Associates LLC Investment ManagersFinance Domain Associates LLC (Domain Associates) is a venture capital firm founded in 1985. The firm is headquartered in Princeton, New Jersey.
One Palmer Square Associates VIII LLC
| 23 years |
| Bruce Greenberg | M | 56 | 5 years | |
| Dennis Podlesak | M | 66 |
RightCare Solutions, Inc.
 RightCare Solutions, Inc. Packaged SoftwareTechnology Services Right Care Solutions, Inc. develops a discharge decision support platform. It offers risk assessment by flagging patients at risk for readmissions when admitted to the hospital. The solution also provides recommendations regarding post-acute care and community-based services for patients. The company was founded by Eric M. Heil and Kathyrn H. Bowles in 2011 and is headquartered in Horsham, PA.
Domain Associates LLC
Domain Associates LLC Investment ManagersFinance Domain Associates LLC (Domain Associates) is a venture capital firm founded in 1985. The firm is headquartered in Princeton, New Jersey. | 17 years |
| Edward E. Schmitt | M | - |
Aesthetic Sciences Corp.
Aesthetic Sciences Corp. Pharmaceuticals: MajorHealth Technology Aesthetic Sciences Corp. provides aesthetic medicine and incontinence products. It develops dermal fillers based on polymer technologies for use in the aesthetic market. The company was founded by Edward Schmitt & Gary Petersmeyer in December 2004 and is headquartered in San Francisco, CA. | 20 years |
| Dean Eliott | M | - |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 8 years |
| Christopher Twomey | M | 64 | 11 years | |
| James A. Gow | M | - | 4 years | |
| Neal Walker | M | 54 | 11 years | |
| Brian Halak | M | 52 |
Domain Associates LLC
Domain Associates LLC Investment ManagersFinance Domain Associates LLC (Domain Associates) is a venture capital firm founded in 1985. The firm is headquartered in Princeton, New Jersey.
One Palmer Square Associates VIII LLC
| 23 years |
| Nicole Vitullo | F | 66 |
Domain Associates LLC
Domain Associates LLC Investment ManagersFinance Domain Associates LLC (Domain Associates) is a venture capital firm founded in 1985. The firm is headquartered in Princeton, New Jersey.
One Palmer Square Associates VIII LLC
| 25 years |
| Anthony P. Ford | M | 59 |
Afferent Pharmaceuticals, Inc.
 Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Afferent Pharmaceuticals, Inc. develops selective drugs for the treatment of debilitating neurogenic disorders. It offers programs for respiratory, cardiovascular, chronic pain, biology, and clinical trials. The firm offers drugs for osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis or bladder pain syndrome. The company was founded by Anthony P. Ford in December 2009 and is headquartered in San Mateo, CA. | 15 years |
| Christina Sun | F | - | 11 years | |
| Stephen Machatha | M | 47 | 3 years | |
| Neil Walker | M | - |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | - |
| Dustin Dickens | M | - |
Xagenic, Inc.
Xagenic, Inc. Medical SpecialtiesHealth Technology Xagenic, Inc. develops the first lab-free molecular diagnostic platform. Its automated diagnostic platform will enable widespread decentralized testing to be performed outside of clinical laboratories. The firm's amplified redox assay detection technology utilizes electrochemical detection methods and does not rely on optical detection components or enzymatic amplification; crude samples can be analyzed with minimal sample processing. The company was founded by Shana O. Kelley and Edward Hartley Sargent in 2010 and is headquartered in Toronto, Canada. | - |
| Gus Likogiannis | M | - |
Xagenic, Inc.
Xagenic, Inc. Medical SpecialtiesHealth Technology Xagenic, Inc. develops the first lab-free molecular diagnostic platform. Its automated diagnostic platform will enable widespread decentralized testing to be performed outside of clinical laboratories. The firm's amplified redox assay detection technology utilizes electrochemical detection methods and does not rely on optical detection components or enzymatic amplification; crude samples can be analyzed with minimal sample processing. The company was founded by Shana O. Kelley and Edward Hartley Sargent in 2010 and is headquartered in Toronto, Canada. | - |
| Gary Phillips | M | 58 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | - |
| Shermaine Tilley | M | 72 |
Xagenic, Inc.
Xagenic, Inc. Medical SpecialtiesHealth Technology Xagenic, Inc. develops the first lab-free molecular diagnostic platform. Its automated diagnostic platform will enable widespread decentralized testing to be performed outside of clinical laboratories. The firm's amplified redox assay detection technology utilizes electrochemical detection methods and does not rely on optical detection components or enzymatic amplification; crude samples can be analyzed with minimal sample processing. The company was founded by Shana O. Kelley and Edward Hartley Sargent in 2010 and is headquartered in Toronto, Canada. | 12 years |
| Dion Madsen | M | 56 |
Xagenic, Inc.
Xagenic, Inc. Medical SpecialtiesHealth Technology Xagenic, Inc. develops the first lab-free molecular diagnostic platform. Its automated diagnostic platform will enable widespread decentralized testing to be performed outside of clinical laboratories. The firm's amplified redox assay detection technology utilizes electrochemical detection methods and does not rely on optical detection components or enzymatic amplification; crude samples can be analyzed with minimal sample processing. The company was founded by Shana O. Kelley and Edward Hartley Sargent in 2010 and is headquartered in Toronto, Canada. | - |
| Ashton Newhall | M | - |
Domain Associates LLC
Domain Associates LLC Investment ManagersFinance Domain Associates LLC (Domain Associates) is a venture capital firm founded in 1985. The firm is headquartered in Princeton, New Jersey. | 18 years |
| Robert Holmlin | M | 56 |
Xagenic, Inc.
Xagenic, Inc. Medical SpecialtiesHealth Technology Xagenic, Inc. develops the first lab-free molecular diagnostic platform. Its automated diagnostic platform will enable widespread decentralized testing to be performed outside of clinical laboratories. The firm's amplified redox assay detection technology utilizes electrochemical detection methods and does not rely on optical detection components or enzymatic amplification; crude samples can be analyzed with minimal sample processing. The company was founded by Shana O. Kelley and Edward Hartley Sargent in 2010 and is headquartered in Toronto, Canada. | 12 years |
| K. Hirth | M | 72 |
Afferent Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Afferent Pharmaceuticals, Inc. develops selective drugs for the treatment of debilitating neurogenic disorders. It offers programs for respiratory, cardiovascular, chronic pain, biology, and clinical trials. The firm offers drugs for osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis or bladder pain syndrome. The company was founded by Anthony P. Ford in December 2009 and is headquartered in San Mateo, CA. | 10 years |
| Ben Bronstein | M | 74 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | - |
| Kathy LaPorte | F | 62 |
Aesthetic Sciences Corp.
Aesthetic Sciences Corp. Pharmaceuticals: MajorHealth Technology Aesthetic Sciences Corp. provides aesthetic medicine and incontinence products. It develops dermal fillers based on polymer technologies for use in the aesthetic market. The company was founded by Edward Schmitt & Gary Petersmeyer in December 2004 and is headquartered in San Francisco, CA. | - |
| Brian H. Dovey | M | 83 |
Domain Associates LLC
Domain Associates LLC Investment ManagersFinance Domain Associates LLC (Domain Associates) is a venture capital firm founded in 1985. The firm is headquartered in Princeton, New Jersey. | 36 years |
| James Blair | M | 84 |
Domain Associates LLC
Domain Associates LLC Investment ManagersFinance Domain Associates LLC (Domain Associates) is a venture capital firm founded in 1985. The firm is headquartered in Princeton, New Jersey. | 39 years |
| Paul Tierney | M | 81 |
Altea Therapeutics Corp.
 Altea Therapeutics Corp. Medical DistributorsDistribution Services Altea Therapeutics Corp. develops pharmaceutical products. It offers PassPort patch, a skin patch that uses short bursts of focused thermal energy to create tiny channels in the surface of the skin and these channels permit the flow of proteins, peptides, carbohydrates, and small molecules into the body without the use of needles. The firm also provides Transdermal vaccine patch, a delivery system for water-soluble drugs and proteins; disease prevention products; insulin skin patch, a non-injectable daily insulin product; and opioid patches that provide delivery of opioids and incorporates the layers of deterrents. The company was founded by Jonathan A Eppstein and Deborah Eppstein in 1998 and is headquartered in Atlanta, GA. | - |
| Richard Couch | M | - |
Altea Therapeutics Corp.
Altea Therapeutics Corp. Medical DistributorsDistribution Services Altea Therapeutics Corp. develops pharmaceutical products. It offers PassPort patch, a skin patch that uses short bursts of focused thermal energy to create tiny channels in the surface of the skin and these channels permit the flow of proteins, peptides, carbohydrates, and small molecules into the body without the use of needles. The firm also provides Transdermal vaccine patch, a delivery system for water-soluble drugs and proteins; disease prevention products; insulin skin patch, a non-injectable daily insulin product; and opioid patches that provide delivery of opioids and incorporates the layers of deterrents. The company was founded by Jonathan A Eppstein and Deborah Eppstein in 1998 and is headquartered in Atlanta, GA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Richard Pascoe | M | 60 |
Somaxon Pharmaceuticals, Inc.
 Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | 5 years |
| David Berger | M | 54 | 10 years | |
| Paul DiPerna | M | 65 | 5 years | |
| Stephen Tulipano | M | 65 | 4 years | |
| Thomas Mathers | M | 56 | 6 years | |
| Thomas Wiggans | M | 72 |
Somaxon Pharmaceuticals, Inc.
Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | 4 years |
| Meg M. McGilley | F | 65 |
Somaxon Pharmaceuticals, Inc.
Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | 6 years |
| Martin Edwards | M | 68 | 3 years | |
| Bernice Kuca | F | 65 | - | |
| David Schopp | M | 75 |
Rensselaer Polytechnic Institute
| 5 years |
| Kenneth M. Cohen | M | 68 |
Somaxon Pharmaceuticals, Inc.
Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | 5 years |
| Cam Garner | M | 75 |
Somaxon Pharmaceuticals, Inc.
Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | - |
| Kathleen Glaub | F | 70 |
Afferent Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Afferent Pharmaceuticals, Inc. develops selective drugs for the treatment of debilitating neurogenic disorders. It offers programs for respiratory, cardiovascular, chronic pain, biology, and clinical trials. The firm offers drugs for osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis or bladder pain syndrome. The company was founded by Anthony P. Ford in December 2009 and is headquartered in San Mateo, CA. | 3 years |
| Tran Nguyen | M | 50 |
Somaxon Pharmaceuticals, Inc.
Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | 3 years |
| Steve Z. Szczepanski | M | - |
Rensselaer Polytechnic Institute
| 5 years |
| Bruce G. McCarthy | M | - |
Afferent Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Afferent Pharmaceuticals, Inc. develops selective drugs for the treatment of debilitating neurogenic disorders. It offers programs for respiratory, cardiovascular, chronic pain, biology, and clinical trials. The firm offers drugs for osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis or bladder pain syndrome. The company was founded by Anthony P. Ford in December 2009 and is headquartered in San Mateo, CA. | 5 years |
| Luc Marengère | M | 59 | 2 years | |
| Doug Roeder | M | 53 | 13 years | |
| Kurt von Emster | M | 56 |
Somaxon Pharmaceuticals, Inc.
Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | 8 years |
| Fred Cohen | M | 67 | 6 years | |
| Fred J. Dotzler | M | 78 |
SenoRx, Inc.
 SenoRx, Inc. Medical SpecialtiesHealth Technology SenoRx, Inc. develops and manufactures invasive devices for the diagnosis and treatment of breast cancer. The company was founded in 1998 and is headquartered in Tempe, AZ. | 12 years |
| Matthew D. Dallas | M | 49 | 2 years | |
| Erle T. Mast | M | 61 |
Somaxon Pharmaceuticals, Inc.
Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | 5 years |
| Scott Glenn | M | 73 |
Somaxon Pharmaceuticals, Inc.
Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | 4 years |
| Robert B. Anacone | M | 73 | 6 years | |
| Matthew Onaitis | M | 53 |
Somaxon Pharmaceuticals, Inc.
Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | 7 years |
| Joshua Reed | M | 51 | 4 years | |
| Brian Dorsey | M | 55 |
Somaxon Pharmaceuticals, Inc.
Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | 8 years |
| Frank James | M | 93 |
Rensselaer Polytechnic Institute
| 3 years |
| Rosenblum Mark | M | - |
Rensselaer Polytechnic Institute
| 4 years |
| Lonnie Smith | M | 79 | 2 years | |
| Henry Anhalt | M | - | - | |
| Kurt C. Wheeler | M | 71 |
Somaxon Pharmaceuticals, Inc.
Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA.
SenoRx, Inc.
SenoRx, Inc. Medical SpecialtiesHealth Technology SenoRx, Inc. develops and manufactures invasive devices for the diagnosis and treatment of breast cancer. The company was founded in 1998 and is headquartered in Tempe, AZ. | 5 years |
| Susan E. Dubé | F | 75 |
Somaxon Pharmaceuticals, Inc.
Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | 6 years |
| Richard Markham | M | 73 | 7 years | |
| William Hart | M | - |
Rensselaer Polytechnic Institute
| 4 years |
| Vincent White | M | - |
Rensselaer Polytechnic Institute
| 4 years |
| Marty Lacoff | M | 76 |
Rensselaer Polytechnic Institute
| 4 years |
| Steven I. Rothman | M | - |
Rensselaer Polytechnic Institute
| 4 years |
| Anthony J. Tether | M | 82 |
Rensselaer Polytechnic Institute
| - |
| Charles G. Hutter | M | - |
Rensselaer Polytechnic Institute
| 4 years |
| Stephen L. Brotman | M | - |
Rensselaer Polytechnic Institute
| 4 years |
| Mike Rosinko | M | - | 9 years | |
| Kristine A. Foss | F | 70 | - | |
| Edward Cahill | M | 71 | 11 years | |
| Kenneth R. Adamo | M | - |
Rensselaer Polytechnic Institute
| 4 years |
| John Buhler | M | 63 |
SenoRx, Inc.
SenoRx, Inc. Medical SpecialtiesHealth Technology SenoRx, Inc. develops and manufactures invasive devices for the diagnosis and treatment of breast cancer. The company was founded in 1998 and is headquartered in Tempe, AZ. | 2 years |
| William C. LaCourse | M | 80 |
Rensselaer Polytechnic Institute
| 3 years |
| Nicholas Donofrio | M | 78 |
Rensselaer Polytechnic Institute
| 4 years |
| Paul J. Severino | M | 77 |
Rensselaer Polytechnic Institute
| 4 years |
| Fang Shin | M | 82 |
Rensselaer Polytechnic Institute
| - |
| Paul F. McLaughlin | M | 78 |
Rensselaer Polytechnic Institute
| 4 years |
| James Watt | M | 74 |
Rensselaer Polytechnic Institute
| 4 years |
| William Holzer | M | - |
Rensselaer Polytechnic Institute
| 6 years |
| Brian Hansen | M | 56 | 7 years | |
| Asish Xavier | M | - | 9 years | |
| Norman Meisner | M | - |
Rensselaer Polytechnic Institute
| 2 years |
| Frederick P. Keller | M | - |
Rensselaer Polytechnic Institute
| 5 years |
| Myles David Brand | M | - |
Rensselaer Polytechnic Institute
| - |
| John C. Decker | M | - |
Rensselaer Polytechnic Institute
| 4 years |
| Bob Louis Cummings | M | 86 |
Rensselaer Polytechnic Institute
| 4 years |
| Edward Goldberg | M | - |
Rensselaer Polytechnic Institute
| 4 years |
| Gary Masner | M | - |
Rensselaer Polytechnic Institute
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 94 | 94.00% |
| Canada | 6 | 6.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jesse I. Treu
- Personal Network
